Syndax Pharmaceuticals vs Vanda Pharmaceuticals
SNDX and VNDA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SNDX and VNDA compare
Syndax Pharmaceuticals is the larger company, worth 3.6 times as much as Vanda Pharmaceuticals ($822M against $230M).
Syndax Pharmaceuticals grew revenue faster over the last twelve months (160% versus 8.1% for Vanda Pharmaceuticals).
Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −120% at Vanda Pharmaceuticals.
Vanda Pharmaceuticals scores higher on the StockData Score (10 against 3 for Syndax Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SNDX | VNDA |
|---|---|---|
| Size and price | ||
| Market cap | $822M | $230M |
| Share price | $9.20 | $3.81 |
| Change, 1 year | −44.6% | −12.4% |
| Change, 5 years | −44.2% | −77.0% |
| Beta (5Y) | 1.72 | 0.78 |
| Employees | 298 | 533 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.8× | 1.0× (better) |
| P/B | – | 1.2× |
| FCF yield | – | −60.8% |
| Fair value | – | $8.53 |
| Margin of safety | – | 55.3% |
| Growth | ||
| Revenue growth (TTM) | 160% (better) | 8.1% |
| Revenue growth, 5Y average | 158% (better) | −2.7% |
| Profitability | ||
| Gross margin | – | 93.6% |
| Operating margin | −61.7% (better) | −77.6% |
| Net margin | −72.3% (better) | −120% |
| FCF margin | – | −61.0% |
| Return on equity | −426% | −82.5% (better) |
| Return on invested capital | – | −52.6% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −44660.0× | – |
| Current ratio | 4.69 (better) | 1.54 |
| Altman Z-score | −2.30 | −1.85 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 121% | 82.2% |
| Held by insiders | 1.8% | 9.2% |
| Insider net buying, 12 months | −$2.9M | −$2.8M (better) |
| Short interest, % of float | 21.6% | 13.9% |
Go deeper
- SNDX stock overview
- SNDX income statement
- SNDX valuation and score
- VNDA stock overview
- VNDA income statement
- VNDA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.